NCT00940667 is a Phase 3 clinical trial of Amlodipine plus Losartan in Hypertension, sponsored by Hanmi Pharmaceutical Company Limited.

Who is sponsoring NCT00940667?

NCT00940667 is sponsored by Hanmi Pharmaceutical Company Limited.

What drugs are being tested in NCT00940667?

Interventions in NCT00940667: Amlodipine plus Losartan, Amlodipine.

What condition does NCT00940667 study?

NCT00940667 studies Hypertension.

Is NCT00940667 still recruiting?

NCT00940667 is currently completed. Last updated 10 October 2016.

Last reviewed 2016-10-10 · How we verify

NCT00940667

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase III, 8-week, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Amlodipine 5mg+Losartan 50mg Versus Amlodipine 10mg in Patients With Essential Hypertension Not Controlled on Amlodipine Monotherapy

Completed Phase 3 Last updated 10 October 2016

What this trial tests

Phase 3 trial testing Amlodipine plus Losartan in Hypertension in 185 participants. Completed in 1 December 2008.

Timeline

1 May 2008

Primary endpoint
1 December 2008

1 December 2008

Quick facts

Lead sponsor	Hanmi Pharmaceutical Company Limited
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	185
Start date	1 May 2008
Primary completion	1 December 2008
Estimated completion	1 December 2008
Sites	1 location across South Korea

Drugs / interventions tested

Amlodipine plus Losartan — full drug profile →
Amlodipine (amlodipine) — full drug profile →

Conditions studied

Hypertension — all drugs for Hypertension →

Sponsor

Hanmi Pharmaceutical Company Limited — full company profile →

Who can join

18 and older, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change from baseline in mean sitting diastolic blood pressure
Time frame: Week 8

Sponsor's own description

The purpose of this study is to evaluate of efficacy and safety of amlodipine plus losartan and amlodipine alone in patients with essential hypertension inadequately controlled on amlodipine monotherapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind phase III noninferiority
Kang SM, Youn JC, Chae SC, Park CG, et al · · 2011 · cited 14× · PMID 22136978 · DOI 10.1016/j.clinthera.2011.11.007
Evaluation of blood pressure reduction response and responder characteristics to fixed-dose combination treatment of amlodipine and losartan: a post hoc analysis of pooled clinical trials.
Unniachan S, Wu D, Rajagopalan S, Hanson ME, et al · · 2014 · cited 5× · PMID 25098858 · DOI 10.1111/jch.12390

Verify or expand the search:

Other trials of Amlodipine plus Losartan

Trials testing the same drug.

NCT03912285 — The Pharmacokinetic Interaction Between Amlodipine and Losartan · Phase 1 · completed

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other Hanmi Pharmaceutical Company Limited trials

Trials by the same sponsor.

NCT07297693 — A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers · Phase 1 · not yet recruiting
NCT06595004 — A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients · Phase 3 · completed
NCT06518122 — A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers · Phase 1 · completed
NCT06481098 — A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects. · Phase 1 · completed
NCT06357910 — A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy V · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00940667 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hanmi Pharmaceutical Company Limited
Last refreshed: 10 October 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00940667.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing